Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-DOS47 + vinorelbine + cisplatin
- Development stage
- Unknown
- Lead developer
- Helix BioPharma
- Modality
- Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
L-DOS47 + vinorelbine + cisplatin is an experimental combination regimen involving three agents: L-DOS47, a targeted immunoconjugate developed to convert tumor microenvironment urea into ammonia and modulate tumor pH; vinorelbine, a semisynthetic vinca alkaloid that inhibits microtubule assembly resulting in mitotic arrest; and cisplatin, a platinum-based chemotherapeutic that causes DNA crosslinking and apoptosis. This combination is primarily being investigated for the treatment of non-small cell lung cancer (NSCLC) and is designed to leverage both cytotoxic and antitumor immune-modulating mechanisms. Vinorelbine and cisplatin are established agents for NSCLC, while L-DOS47 is under clinical evaluation as an immunotherapy.
- Other names
- NP chemotherapyVP chemotherapy
02
Targets
CEACAM6TUBB (Tubulin (alpha and beta subunits))N7-G (DNA guanine-N7 adduct)
Beyond the preview
Go deeper on L-DOS47 + vinorelbine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L-DOS47 + vinorelbine + cisplatin.